Martin Rogers (born 1981) is an Australian bioentrepreneur who has been associated since 2007 with a number of ASX-listed biotechnology companies, including Prima BioMed, which he led from 2007 to 2012.
Rogers attended the University of New South Wales between 1999 and 2004 where he gained a double degree in chemical engineering and computer science.
[1] Rogers was part of an investor group that effectively took control of Prima BioMed in late 2007, when he was appointed a director.
At that time Prima had Phase IIa data for its CVac cancer vaccine product, but did not have the funds to progress further.
[18] In 2018, Martin Rogers, of KTM Ventures, co-invested with Mike Tilley to purchase a 30% stake in cryptocurrency exchange Independent Reserve.